sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.
|
ISUPREL
|
halothane
|
ADVISE
|
Isoproterenol_ddi.xml
|
DDI-DrugBank.d55.s2
|
DDI-DrugBank.d55.s2.p1
|
Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;
|
Antacids
|
chloroquine
|
MECHANISM
|
Chloroquine_ddi.xml
|
DDI-DrugBank.d429.s0
|
DDI-DrugBank.d429.s0.p8
|
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.
|
acetaminophen
|
HMG-CoA reductase inhibitors
|
NONE
|
Finasteride_ddi.xml
|
DDI-DrugBank.d209.s3
|
DDI-DrugBank.d209.s3.p25
|
Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.
|
cyclosporine
|
allopurinol sodium
|
MECHANISM
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s22
|
DDI-DrugBank.d413.s22.p2
|
Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.
|
thyroid
|
estrogens
|
ADVISE
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s14
|
DDI-DrugBank.d54.s14.p0
|
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
|
dexamethasone
|
EGF
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s7
|
DDI-MedLine.d12.s7.p4
|
Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.
|
Erythromycin
|
erythromycin
|
NONE
|
Atorvastatin_ddi.xml
|
DDI-DrugBank.d140.s9
|
DDI-DrugBank.d140.s9.p2
|
Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
|
clozapine
|
phenothiazines
|
ADVISE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s30
|
DDI-DrugBank.d480.s30.p1
|
The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.
|
cefdinir
|
iron
|
MECHANISM
|
Cefdinir_ddi.xml
|
DDI-DrugBank.d420.s11
|
DDI-DrugBank.d420.s11.p0
|
Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see a href= frova_od.htm#CI CONTRAINDICATIONS).
|
methysergide
|
FROVA
|
ADVISE
|
Frovatriptan_ddi.xml
|
DDI-DrugBank.d426.s1
|
DDI-DrugBank.d426.s1.p9
|
The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.
|
Robinul
|
antiparkinson drugs
|
EFFECT
|
Glycopyrrolate_ddi.xml
|
DDI-DrugBank.d510.s0
|
DDI-DrugBank.d510.s0.p2
|
Effects of Erythromycin on Felbatol The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.
|
Felbatol
|
felbamate
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s36
|
DDI-DrugBank.d434.s36.p4
|
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
|
estazolam
|
barbiturates
|
MECHANISM
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s4
|
DDI-DrugBank.d338.s4.p3
|
Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.
|
indomethacin
|
beta blockers
|
EFFECT
|
Atenolol_ddi.xml
|
DDI-DrugBank.d73.s6
|
DDI-DrugBank.d73.s6.p0
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
cimetidine
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p3
|
The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests.
|
diazepam
|
indomethacin
|
NONE
|
11210678.xml
|
DDI-MedLine.d67.s1
|
DDI-MedLine.d67.s1.p6
|
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
|
Vitamin D3
|
Cholestyramine
|
NONE
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s0
|
DDI-DrugBank.d98.s0.p15
|
Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3.
|
alcohol
|
alcohol
|
NONE
|
6536292.xml
|
DDI-MedLine.d54.s8
|
DDI-MedLine.d54.s8.p2
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
b-adrenergic blocking agents
|
sulfonylureas
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p259
|
FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.
|
FLEXERIL
|
CNS depressants
|
EFFECT
|
Cyclobenzaprine_ddi.xml
|
DDI-DrugBank.d150.s1
|
DDI-DrugBank.d150.s1.p2
|
Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.
|
vitamin D
|
corticosteroids
|
EFFECT
|
Cholecalciferol_ddi.xml
|
DDI-DrugBank.d404.s11
|
DDI-DrugBank.d404.s11.p2
|
Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.
|
Quinolones
|
norfloxacin
|
NONE
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s5
|
DDI-DrugBank.d217.s5.p0
|
Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.
|
rifampin
|
ketoconazole
|
MECHANISM
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s24
|
DDI-DrugBank.d458.s24.p0
|
Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
|
Dexbrompheniramine
|
CNS depressants
|
INT
|
Dexbrompheniramine_ddi.xml
|
DDI-DrugBank.d62.s0
|
DDI-DrugBank.d62.s0.p1
|
Phenytoin: Isoniazid may increase serum levels of phenytoin.
|
Isoniazid
|
phenytoin
|
MECHANISM
|
Isoniazid_ddi.xml
|
DDI-DrugBank.d187.s9
|
DDI-DrugBank.d187.s9.p2
|
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.
|
acetaminophen
|
lidocaine
|
NONE
|
11206047.xml
|
DDI-MedLine.d111.s5
|
DDI-MedLine.d111.s5.p8
|
Potential for ABILIFY to Affect Other Drugs Aripiprazole is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes.
|
ABILIFY
|
Aripiprazole
|
NONE
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s24
|
DDI-DrugBank.d509.s24.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
delavirdine
|
risperidone
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p464
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
isoniazid
|
quinupristin
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p255
|
Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
|
Vitamin D
|
digitalis
|
ADVISE
|
Calcitriol_ddi.xml
|
DDI-DrugBank.d384.s7
|
DDI-DrugBank.d384.s7.p2
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
colistin
|
lithium
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p101
|
The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.
|
ranitidine
|
cisapride
|
MECHANISM
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s11
|
DDI-DrugBank.d237.s11.p2
|
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.
|
aspirin
|
salicylates
|
NONE
|
Fenoprofen_ddi.xml
|
DDI-DrugBank.d154.s2
|
DDI-DrugBank.d154.s2.p8
|
Itraconazole Ketoconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone Cyclosporine Large quantities of grapefruit juice ( 1 quart daily)
|
Telithromycin
|
Cyclosporine
|
NONE
|
Lovastatin_ddi.xml
|
DDI-DrugBank.d567.s5
|
DDI-DrugBank.d567.s5.p24
|
If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.
|
antacid
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s10
|
DDI-DrugBank.d48.s10.p0
|
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.
|
phenothiazines
|
metoclopramide
|
NONE
|
Bromocriptine_ddi.xml
|
DDI-DrugBank.d272.s2
|
DDI-DrugBank.d272.s2.p5
|
The response to Factrel may be blunted by phenothiazines and dopamine antagonists which cause a rise in prolactin.
|
Factrel
|
phenothiazines
|
EFFECT
|
Gonadorelin_ddi.xml
|
DDI-DrugBank.d369.s3
|
DDI-DrugBank.d369.s3.p0
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
quinine
|
valproate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p338
|
Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.
|
HMG-CoA reductase inhibitors
|
CRIXIVAN
|
ADVISE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s72
|
DDI-DrugBank.d97.s72.p8
|
Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.
|
carbamazepine
|
carbamazepine
|
NONE
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s30
|
DDI-DrugBank.d565.s30.p2
|
Boric acid may interact with the idoxuridine preparation causing a gritty substance to form or may interact with the preservative in the idoxuridine preparation causing a toxic effect in the eye.
|
Boric acid
|
idoxuridine
|
MECHANISM
|
Idoxuridine_ddi.xml
|
DDI-DrugBank.d91.s3
|
DDI-DrugBank.d91.s3.p0
|
H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
|
proton pump inhibitors
|
dasatinib
|
EFFECT
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s11
|
DDI-DrugBank.d48.s11.p17
|
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.
|
clonazepam
|
propantheline
|
MECHANISM
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s3
|
DDI-DrugBank.d333.s3.p0
|
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.
|
dopamine antagonists
|
metoclopramide
|
EFFECT
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s3
|
DDI-DrugBank.d357.s3.p28
|
Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, antihypertensive agents, or other vasodilators.
|
diuretics
|
vasodilators
|
NONE
|
Epoprostenol_ddi.xml
|
DDI-DrugBank.d241.s0
|
DDI-DrugBank.d241.s0.p4
|
Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.
|
diltiazem
|
triazolam
|
MECHANISM
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s33
|
DDI-DrugBank.d565.s33.p1
|
1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.
|
aripiprazole
|
antihypertensive agents
|
EFFECT
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s2
|
DDI-DrugBank.d509.s2.p0
|
Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.
|
Midazolam
|
morphine
|
EFFECT
|
11210678.xml
|
DDI-MedLine.d67.s7
|
DDI-MedLine.d67.s7.p0
|
In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone;
|
(+)-NANM
|
PCP
|
NONE
|
3968644.xml
|
DDI-MedLine.d30.s8
|
DDI-MedLine.d30.s8.p3
|
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
|
benzodiazepines
|
nefazodone
|
MECHANISM
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s8
|
DDI-DrugBank.d338.s8.p0
|
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.
|
cerulein
|
3H-spiroperidol
|
NONE
|
2857100.xml
|
DDI-MedLine.d15.s0
|
DDI-MedLine.d15.s0.p6
|
Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.
|
Cytosine arabinoside
|
flucytosine
|
EFFECT
|
Flucytosine_ddi.xml
|
DDI-DrugBank.d453.s0
|
DDI-DrugBank.d453.s0.p1
|
Effects of Other Antiepileptic Drugs on Felbatol Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol as compared to the same dose of Felbatol given as monotherapy.
|
Phenytoin
|
felbamate
|
MECHANISM
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s30
|
DDI-DrugBank.d434.s30.p22
|
Potential for reduction in anticonvulsant and/or efavirenz plasma levels;
|
anticonvulsant
|
efavirenz
|
MECHANISM
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s75
|
DDI-DrugBank.d531.s75.p0
|
Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
nefazodone
|
cisapride
|
MECHANISM
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s6
|
DDI-DrugBank.d237.s6.p3
|
Certain antibiotic, cisplatin, cyclosporine, diuretic, foscarnet, and vaccines.
|
foscarnet
|
vaccines
|
NONE
|
Bleomycin_ddi.xml
|
DDI-DrugBank.d554.s0
|
DDI-DrugBank.d554.s0.p14
|
Prednisolone: Ethinyl estradiol may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.
|
Ethinyl estradiol
|
prednisolone
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s31
|
DDI-DrugBank.d485.s31.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
dextrothyroxine
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p14
|
or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.
|
multivitamins
|
quinolone
|
NONE
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s16
|
DDI-DrugBank.d395.s16.p1
|
Cholestyramine and Charcoal Administration of cholestyramine or activated charcoal in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of leflunomide) concentration .
|
Charcoal
|
activated charcoal
|
NONE
|
Leflunomide_ddi.xml
|
DDI-DrugBank.d41.s0
|
DDI-DrugBank.d41.s0.p5
|
Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.
|
tetracycline
|
digoxin
|
MECHANISM
|
Digoxin_ddi.xml
|
DDI-DrugBank.d450.s3
|
DDI-DrugBank.d450.s3.p15
|
There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.
|
buprenorphine
|
benzodiazepines
|
EFFECT
|
Buprenorphine_ddi.xml
|
DDI-DrugBank.d380.s4
|
DDI-DrugBank.d380.s4.p0
|
MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .
|
bupropion
|
phenelzine
|
EFFECT
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s19
|
DDI-DrugBank.d5.s19.p4
|
Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
|
Cypermethrin
|
allopurinol
|
EFFECT
|
11137320.xml
|
DDI-MedLine.d126.s0
|
DDI-MedLine.d126.s0.p1
|
Avoid the concomitant use of chlorprothixene and tramadol (Ultram).
|
tramadol
|
Ultram
|
NONE
|
Chlorprothixene_ddi.xml
|
DDI-DrugBank.d503.s3
|
DDI-DrugBank.d503.s3.p2
|
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
|
Type 1C antiarrhythmics
|
propafenone
|
NONE
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s7
|
DDI-DrugBank.d223.s7.p12
|
However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.
|
buspirone
|
warfarin
|
EFFECT
|
Buspirone_ddi.xml
|
DDI-DrugBank.d463.s6
|
DDI-DrugBank.d463.s6.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
aminoglycosides
|
procainamide
|
NONE
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p37
|
Indinavir concentrations may be decreased in the presence of nevirapine.
|
Indinavir
|
nevirapine
|
MECHANISM
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s47
|
DDI-DrugBank.d97.s47.p0
|
Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.
|
statins
|
lovastatin
|
NONE
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s27
|
DDI-DrugBank.d289.s27.p3
|
Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.
|
furosemide
|
acetylsalicylic acid
|
EFFECT
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s13
|
DDI-DrugBank.d231.s13.p0
|
WelChol decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.
|
verapamil
|
Calan SR
|
NONE
|
Colesevelam_ddi.xml
|
DDI-DrugBank.d551.s2
|
DDI-DrugBank.d551.s2.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
lamotrigine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p21
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Felbatol
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p11
|
Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.
|
EQUETROTM
|
phenobarbital
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s8
|
DDI-DrugBank.d94.s8.p4
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
aminosalicylic acid
|
cinchophen
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p167
|
Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
|
Mefloquine
|
chloroquine
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s5
|
DDI-DrugBank.d220.s5.p2
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
mitotane
|
phenobarbital
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p517
|
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid.
|
thiazides
|
corticosteroids
|
NONE
|
Acarbose_ddi.xml
|
DDI-DrugBank.d536.s1
|
DDI-DrugBank.d536.s1.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
indomethacin
|
trimethoprim
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1017
|
Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.
|
SUSTIVA
|
ritonavir
|
ADVISE
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s63
|
DDI-DrugBank.d531.s63.p0
|
Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
|
NaCMC
|
NaFlu
|
NONE
|
11154900.xml
|
DDI-MedLine.d76.s10
|
DDI-MedLine.d76.s10.p1
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
protease inhibitors
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p33
|
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
|
Macrolide antibiotics
|
cerivastatin
|
MECHANISM
|
11197581.xml
|
DDI-MedLine.d25.s12
|
DDI-MedLine.d25.s12.p2
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
ranitidine
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p19
|
Quinolones have also been shown to interfere with the metabolism of caffeine.
|
Quinolones
|
caffeine
|
MECHANISM
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s3
|
DDI-DrugBank.d562.s3.p0
|
Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.
|
diltiazem hydrochloride
|
digoxin
|
MECHANISM
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s18
|
DDI-DrugBank.d565.s18.p0
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
paraldehyde
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p17
|
Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.
|
erythromycin
|
valproate
|
INT
|
Dirithromycin_ddi.xml
|
DDI-DrugBank.d522.s24
|
DDI-DrugBank.d522.s24.p7
|
Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.
|
cypermethrin
|
allopurinol
|
EFFECT
|
11137320.xml
|
DDI-MedLine.d126.s7
|
DDI-MedLine.d126.s7.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
alcohol
|
bromelains
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p59
|
Central nervous system depressant (CNS) drugs including alcohol, antidepressants, antihistamines, antipsychotics, blood pressure medications (reserpine, methyldopa, beta-blockers), motion sickness medications, muscle relaxants, narcotics, sedatives, sleeping pills and tranquilizers
|
Central nervous system depressant
|
antidepressants
|
NONE
|
Citalopram_ddi.xml
|
DDI-DrugBank.d472.s0
|
DDI-DrugBank.d472.s0.p1
|
Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.
|
anticoagulants
|
Fluvoxamine
|
ADVISE
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s31
|
DDI-DrugBank.d76.s31.p0
|
d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
|
d-amphetamine
|
desipramine
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s8
|
DDI-DrugBank.d236.s8.p0
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
antiarrhythmics
|
antihistamines
|
NONE
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p43
|
INDOCIN and triamterene should not be administered together.
|
INDOCIN
|
triamterene
|
ADVISE
|
Indomethacin_ddi.xml
|
DDI-DrugBank.d82.s29
|
DDI-DrugBank.d82.s29.p0
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
glimepiride
|
Trilisate
|
ADVISE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p3
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Felbatol
|
Prelone
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p487
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
oxyphenbutazone
|
quinine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1302
|
Animal studies indicate that dobutamine may be ineffective if the patient has recently received a b-blocking drug.
|
dobutamine
|
b-blocking drug
|
EFFECT
|
Dobutamine_ddi.xml
|
DDI-DrugBank.d274.s0
|
DDI-DrugBank.d274.s0.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.